South Korea's pharmaceutical giant Celltrion Inc. said Monday that it has received approval from Canadian health authorities ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has begun commercial operation of its third manufacturing plant in the country. The plant in Incheon, just west of Seoul, ...

South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Celltrion today presented additional data from a Phase III randomized controlled trial (RCT) for CT-P41, a biosimilar candidate referencing PROLIA®/XGEVA® (denosumab) in postmenopausal women ...

As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this month, Celltrion launched STEQEYMA in both Germany and ...

South Korea's antitrust regulator on Tuesday said it has fined leading drugmaker Celltrion 435 million won ($309,900) for ...

Celltrion, which provided unfair profits to affiliates with a high stake in Chairman Seo Jeong-jin, will be fined 435 million won by the Fair Trade Commission ...

Celltrion today presented additional data from a Phase III randomized controlled trial (RCT) for CT-P41, a biosimilar candidate referencing PROLIA®/XGEVA® (denosumab) in postmenopausal women with ...